Exhibit 1.1

                                               CONTACTS:

                                               Kevin Langin, Media Relations
                                               MDS Pharma Services
                                               kevin.langin@mdsps.com
                                               402-476-2811, Ext. 4938

                                               Bonnie Ortega, Investor Relations
                                               CardioDynamics
                                               bortega@cardiodynamics.com
                                               888-522-2342, Ext. 1005

                                               Irene Paigah, Media Relations
                                               CardioDynamics
                                               ipaigah@cardiodynamics.com
                                               888-522-2342, Ext. 1012


                     MDS Pharma Services and CardioDynamics
                           Announce Strategic Alliance

  BioZ Available at the Leading CRO's Early Clinical Research Centers Worldwide

MONTREAL, CANADA and SAN DIEGO, CA--February 9, 2004--MDS Pharma Services, a
leading provider of innovative drug discovery and development solutions and
subsidiary of MDS, Inc. (NYSE: MDZ; TSX: MDS), and CardioDynamics (Nasdaq:
CDIC), the innovator and leader of Impedance Cardiography (ICG) technology,
today announced that the companies have formed a strategic alliance to offer
CardioDynamics' BioZ ICG hemodynamic monitoring solution at MDS Pharma Services'
Early Clinical Research centers worldwide.

"MDS Pharma Services is a leading provider of technologies and methods that
allow early and rapid assessment of new drug compounds," said Jerry Merritt,
Senior Vice President & General Manager, Early Clinical Research.
"CardioDynamics' innovative ICG technology can provide our customers with
noninvasive and cost-effective access to the important hemodynamic data they
need to test and monitor the effects of new medications and treatment programs
in Phase I and II clinical trials."



"With MDS Pharma Services' global presence and solid reputation, CardioDynamics
has the opportunity to contribute to drug development and also increase its
exposure to pharmaceutical leaders," stated Michael K. Perry, Chief Executive
Officer of CardioDynamics. "Pfizer Global Research, Glaxo SmithKline, and Eli
Lilly are already using our BioZ Systems for their research. The objective is
for patients to have access to new medications and treatment programs as soon as
possible. Both companies are committed to providing pharmaceutical partners with
the tools and solutions they need to make this happen."

BioZ ICG's proprietary technology uses sensors on the neck and chest to quickly
provide noninvasive access to vital cardiac parameters, including the amount of
blood pumped by the heart each minute (cardiac output), and the force the heart
has to pump against to deliver blood to the extremities (systemic vascular
resistance). The BioZ's measurements provide researchers insight into the
blood-flow and cardiovascular effects--both desirable and undesirable--of
potential new medications under study. Prior to the BioZ, blood-flow monitoring
in pharmaceutical clinical trials was typically limited to monitoring heart rate
and blood pressure and did not provide a complete picture of a patient's status
and response to a drug.

About MDS Pharma Services:

MDS Pharma Services offers a full spectrum of resources to meet the drug
discovery and development needs of the pharmaceutical and biotechnology
industries. With numerous facilities strategically located around the world, the
company applies advanced scientific and technological expertise to each stage of
the drug discovery and development process -- early stage: lead optimization,
pre-IND research and development, early clinical research (bioequivalence,
phases I-IIa) and bioanalysis; and late stage: global clinical development
(phases IIb-IV) and central lab. For more information, visit MDS Pharma
Services' Web site at www.mdsps.com.

MDS Pharma Services is part of MDS Inc. (NYSE: MDZ; Toronto: MDS), an
international health and life sciences company. At MDS Inc., our 10,000 highly
skilled people provide services, products and instruments enabling health
sciences organizations to enhance the well being of people around the world. We
focus on helping discover and test new drugs, assisting doctors to diagnose and
treat patients and preventing the spread of disease. Find out more about MDS
Inc. (TSX: MDS; NYSE: MDZ), at www.mdsintl.com or by calling 1-888-MDS-7222, 24
hours a day.



About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
breakthrough medical technology called Impedance Cardiography (ICG). The
Company's BioZ(R) Systems are being used by leading physicians around the world
to help battle the number one killer of men and women - cardiovascular disease.
Partners include GE Medical Systems Information Technologies and Philips Medical
Systems. The worldwide market potential for BioZ products is estimated to be $5
billion and an additional $800 million in recurring annual revenue for sensors.
For additional information or to request an investor package, please refer to
the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press
release contains forward-looking statements, such as market size, potential,
growth and penetration rates, the accuracy of which is necessarily subject to
uncertainties and risks including the Company's sole dependence on the BioZ
product line, and various uncertainties characteristic of early growth
companies, as well as other risks detailed in the Company's filings with the
SEC, including its 2002 Form 10-K. The Company does not undertake to update the
disclosures contained in this press release.